Over 10 years we help companies reach their financial and branding goals. Maxbizz is a values-driven consulting agency dedicated.

Gallery

Contact

+1-800-456-478-23

411 University St, Seattle

maxbizz@mail.com

Sona Nanotech Closes Private Placement Financing to Raise $750,000 in Gross Proceeds and Announces Additional Financing

Sona Nanotech Closes Private Placement Financing to Raise $750,000 in Gross Proceeds and Announces Additional Financing

Halifax, Nova Scotia — (Newsfile Corp. – November 27, 2023) – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that it has closed its private placement that was announced on October 18, 2023  with the issuance of 3,750,000 shares at $0.20 per share and 1,875,000 common share purchase warrants […]

Sona Provides Corporate Update on Operating Activities

Sona Provides Corporate Update on Operating Activities

Halifax, Nova Scotia — (Newsfile Corp. – October 12, 2023) – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”), a nanotechnology life sciences company with proprietary manufacturing technology for biocompatible gold nanorods (“GNRs”), is pleased to provide an update on the status of its current operating activities, notably the development of its Targeted Hyperthermia […]

Sona’s ‘THT’ Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona’s ‘THT’ Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Halifax, Nova Scotia — (Newsfile Corp. – September 11, 2023) – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the “Research Group”). This study aims to evaluate the efficacy of Sona’s Targeted Hyperthermia Therapy (“THT”) technology […]

Sona to Engage with Medical Experts and Payors to Inform Regulatory and Commercialization Strategies for Its ‘THT’ Cancer Therapy

Sona to Engage with Medical Experts and Payors to Inform Regulatory and Commercialization Strategies for Its ‘THT’ Cancer Therapy

Halifax, Nova Scotia — (Newsfile Corp. – September 5, 2023) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce it has partnered with EXCITE International (“EXCITE”), a global network of senior specialist physicians, payors, health systems, and end-users, to help guide the development of Sona’s Targeted Hyperthermia Therapy. […]

New NCL Assessment of Sona’s GNR Technology Highlights Process Improvement Success

New NCL Assessment of Sona’s GNR Technology Highlights Process Improvement Success

Halifax, Nova Scotia — (Newsfile Corp. – June 8, 2023) – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that it has received the third set of results of an independent assessment of its proprietary gold nanorod nanoparticles from the U.S. National Cancer Institute’s Nanotechnology Characterization Laboratory (“NCL”).  In […]

Sona Nanotech, is pleased to announce the selection of Minnetronix Medical to engineer the next generation of its infrared light device.

Sona Nanotech Selects Minnetronix to Engineer Its Next Generation Targeted Hyperthermia Cancer Therapy Light Device

Halifax, Nova Scotia — (Newsfile Corp. – May 30, 2023) – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”), a nanotechnology company developing pre-clinical Targeted Hyperthermia Therapy (“THT”) for colorectal cancer, is pleased to announce the selection of Minnetronix Medical to engineer the next generation of its infrared light device. The device will […]

Positive Results of Second Assessment of Sona’s GNR Technology from U.S. Nanotechnology Characterization Laboratory

Positive Results of Second Assessment of Sona’s GNR Technology from U.S. Nanotechnology Characterization Laboratory

Halifax, Nova Scotia — (Newsfile Corp. – April 17, 2023) – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that it has received the second set of results of an independent assessment of its proprietary gold nanorod nanoparticles from the U.S. National Cancer Institute’s Nanotechnology Characterization Laboratory (“NCL”).  […]

  • 1
  • 2